SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits
on the evolution and progression of cardiomyopathy and nephropathy, which is …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce heart failure events by
direct action on the failing heart that is independent of changes in renal tubular function. In …

Doxorubicin (DOX) is a powerful and commonly used chemotherapeutic drug, used alone or
in combination in a variety of cancers, while it has been found to cause serious cardiac side …

Cell death can be executed through distinct subroutines. PANoptosis is a unique
inflammatory cell death modality involving the interactions between pyroptosis, apoptosis …

Rationale: Chemotherapy is a common clinical strategy for cancer treatment. However, the
accompanied cardiomyopathy renders cancer patients under risk of another life-threatening …

Background Therapies are urgently required to ameliorate pathological cardiac hypertrophy
and enhance cardiac function in heart failure. Our preliminary experiments have …

Background Current paradigms of anti-tumor therapies are not qualified to evacuate the
malignancy ascribing to cancer stroma's functions in accelerating tumor relapse and …

Doxorubicin (DOX) is a highly effective and extensively used chemotherapeutic drug but is
limited by its cardiotoxicity. In our previous study, we showed that DOX-induced …

The metabolic patterns and energetics of human induced pluripotent stem cell-derived
cardiomyocytes (HiPSC-CMs) are much less than those of normal adult cardiomyocytes …

Cardiovascular diseases (CVDs) are one of the primary causes of mortality worldwide. An
optimal mitochondrial function is central to supplying tissues with high energy demand, such …